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In retrospect it is funny to recall how reluctant we were when first approached by the J. Phys. D 
commissioning editor, Kevin O’Grady, with the idea of contributing to a set of review articles on 
biomedical applications of magnetic nanoparticles.  It was a novel concept to have not just one 
article but three, written by different groups, and covering, in turn, the synthesis of magnetic 
nanoparticles, their biomolecular functionalisation, and – in our part – the underlying physical 
principles of their application in biomedicine. It seemed like a curious way to encourage multi-
disciplinary R&D – by separating out the chemistry, biology and physics into discrete parts – but 
Kevin was a persuasive advocate, and we agreed to give it a go. 
 
It turned out to be rather liberating to be asked to focus on the physics. We set out to provide 
an easy-to-read resource for non-experts, and as such started by reviewing some of the 
relevant basic concepts of magnetism, including the classification of different magnetic 
materials, and leading on to a description of superparamagnetism. This was not as easy as we 
had expected – and gave us an appreciation for the work that goes into writing good textbooks. 
We went on to describe how a magnetic field can exert a force at a distance, and the physics of 
magnetic actuation. This section turned out to be something of a compromise between clarity 
and complexity, in that we did not go into as much detail as we’d have liked – for example to 
draw out the 3x3 tensor nature of the m • 𝛁 operator – so as not to scare off the reader. We 
then described the way that energy can be transferred from an excitation field into a magnetic 
dipole, and how this can be harnessed via magnetic field hyperthermia. Lastly, acting on a last 
minute suggestion from the editor, we attempted to demystify the physics of magnetic 
resonance imaging (MRI), and the role of magnetic nanoparticles as MRI contrast agents. This 
turned out to be challenging too, as we found out when we asked an MRI expert colleague to 
read and comment on our description, and the best he could say was ‘well, it’s not how I would 
put it, but at least it’s not wrong’. Faint praise indeed, but looking back on it, our description, 
despite being so simplified, does seem to have served our purpose well. 
 
Not everything went well on the physics side. We had a rude awakening when, in 2014, we 
found ourselves the subject of an internet blog post by Douglas Natelson entitled ‘Bad physics 
as a marker for tracking text recycling’. At the heart of this was a sentence in the introduction 
to the article that read ‘Second, the nanoparticles are magnetic, which means that they obey 
Coulomb’s law, and can be manipulated by an external magnetic field gradient.’ – which, on 
inspection, is at best enigmatic, and at worst just wrong. We had missed this at the proofing 
stage, and for a decade thereafter. It was the result of a botched shortening of a passage 
alluding to the magnetic Coulomb law as it relates to forces between acicular particles where 
the dipoles may be treated as well-separated monopoles – and was very embarrassing. Even 
worse was that Douglas pointed out that the phrase has turned up, verbatim, in subsequent 
publications by entirely independent groups and authors. We can only apologise for this, and 
hope that others will take it as a salutary message to always be assiduous when proof reading. 
 
 
Returning to the article itself, the other main theme we explored, alongside the underlying 
physics, was the applications space, including prospects for translational advances in magnetic 
actuation, drug delivery, hyperthermia and MRI contrast agents. Looking back it seems that in 
2003 we were on the cusp of a major expansion of both academic and commercial effort in 
these areas, and that the high citation metrics that the review received (more than 4,500 to 
date) owes a lot to this increase in activity in the ensuing years. It seems that once the physical 
principles were clearly laid out, new discoveries and applications came at a rapid pace.  
 
That said, there remain very few examples of new magnetic nanoparticle applications finding 
their way into everyday clinical use – that is, beyond the pre-existing examples of MRI agents 
and in vitro magnetic immunoassays and bioassays. This most likely reflects the truism that it 
always takes much longer to bring a new technology to the market than you expect. Even so, 
there is some justification for optimism that the fruits of all the labour may soon be coming 
through. This is in part a reflection of the dedicated and sustained efforts that thousands of 
researchers have been making over the last 10-15 years – a significant fraction of many 
individuals’ research careers – working in interdisciplinary teams with a focus on achieving real 
translational results. As a result of this work we now know much more about the ways that 
magnetic nanoparticles behave in the human body than we did in 2003, and we are much 
better able to control and manipulate them safely. A second cause for optimism is that dozens 
of new companies have been formed since 2003 with the express purpose of delivering the new 
applications into the healthcare market.  
 
For this reason, we look ahead to the next ten years with both hope and confidence for the 
continuing growth and success of the field. Not everything that has been proposed or 
championed will find its way into clinical use, but more and more applications will successfully 
make the transition. Ultimately, given the unique properties of magnetic nanoparticles, and the 
many ways they can be exploited to perform safe and beneficial functions for human health, we 
think that that is the most important thing. 
 
Quentin Pankhurst, Stephen Jones & Jon Dobson 
 
 
